Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICON Goes Local As China CRO Market Heats Up

This article was originally published in PharmAsia News

Executive Summary

Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.

You may also be interested in...



Large Chinese CROs To Benefit From Continued Outsourcing Trend, CRO Surveys Say

As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry

China's Tasly Focuses On Plant-based Medicines To Gain Entry To U.S.Market

SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market

Spurred By Demand For Global And Regional Trials In India, China And Japan, ICON Charts Asia Growth Strategy

SINGAPORE - Malcolm Burgess, Executive VP Asia Pacific with Ireland-headquartered ICON Plc - one of the fastest growing contract research organizations in Asia - expresses satisfaction that over the past seven years he could develop a close bonding with his 600 plus staffers based in the medium-sized cities of Chennai and Thiruvananthapuram at the southern tip of India

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel